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ABSTRACT
Worldwide, more than 1 million infants die as a result of premature birth. In the United
States, where 1 in 10 births occurs preterm, premature birth is the leading cause of infant
mortality. Premature infants have high rates of mortality and morbidity, with the highest rates
seen in those infants born extremely preterm—prior to 30 weeks gestation. Severe morbidity in
these infants often contributes to life-long health problems. Maternal hypertension (HTN) is one
contributor to preterm birth and also contributes to fetal growth restriction, resulting in birth
weights which are small for gestational age (SGA, and generally within the lowest 10th
percentile). Within this high risk population, SGA infants have increased risk of mortality
compared to appropriate for gestational age infants. Therefore the impact of maternal HTN on
neonatal outcome might be presumed to be negative. Previous studies however, have been
contradictory, with both higher and lower rates of infant mortality reported in infants born to
mothers with HTN, as well as differing reports analyzing the relationship between serious
morbidity and maternal HTN.
Utilizing the Vermont Oxford Network Very Low Birth Weight database, a collaborative
database of Level III Neonatal Intensive Care Units across the world, 88,275 North American
infants born between 22+0 and 29+6 weeks gestational age between 2008 and 2011 were
identified. This dissertation explores the relationship between maternal HTN and gestational age
at time of birth within this population, and the reported rates of morbidity and mortality in infants
born prior to 30 weeks gestation. The independent contributions of maternal HTN with neonatal
morbidity and mortality in our population were estimated using logistic regression and adjusting
for factors previously known to be associated with risk, including birth weight, antenatal steroid
exposure, infant sex, maternal race/ethnicity, prenatal care, inborn/outborn status, and birth year.
We hypothesized that mortality rates would be lower for infants born to mothers with HTN
compared to those born due to other factors, when corrected for the noted confounding variables
and surviving infants would have better prognoses, as evidenced by lower rates of severe
morbidity, including bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular
leukomalacia, necrotizing enterocolitis, and infection. Within the higher-risk SGA population, we
hypothesized that mortality rates would be higher than observed in appropriately grown infants,
but decreased in those born to mothers with HTN, despite the association between maternal HTN
and SGA.
This dissertation begins with an explanation of current knowledge about preterm birth,
maternal HTN, and their associations. Chapter 2 focuses on the relationship between maternal
HTN and infant mortality in extremely preterm infants. Chapter 3 examines the risk associated
with severe morbidities in surviving infants. In addition, we also use a combined morbidity risk
assessment score which has previously been used to determine future risk of long term disability.
In Chapter 4, SGA infants are separately evaluated for their risk of mortality and the association
with maternal HTN.
These analyses support the high mortality and morbidity rates seen in extremely
preterm infants. Maternal HTN, after adjustment, results in reduced risk of both mortality and
severe morbidities in infants compared to infants born to mothers with other underlying
contributors to preterm birth. This suggests that clinical practices and parental counseling should
reflect differing risk profiles in sub-populations of extremely preterm infants.
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CHAPTER 1: MATERNAL HYPERTENSION INFLUENCES MORTALITY
AND MORBIDITY IN EXTREMELY PRETERM INFANTS

1.1. Preterm Birth
Preterm birth rates in developed countries that track population data, including the
United States, United Kingdom, and Scandinavian countries, demonstrate dramatic
increases in preterm birth rates over the past 20 years.1,2 This is attributed to an increase
in multiple births, use of artificial reproductive therapy for conception, an increase in
elderly primiparas, as well as changes in clinical practice which result in higher cesareansections and better identification of gestational age due to early pregnancy ultrasound
dating. It is estimated that 9.6% of all births occur prior to 37 weeks gestation, with 85%
of those occurring in Africa and Asia. Additionally, over half a million preterm births
occur in each Europe and North America, and 900,000 in Latin America and the
Caribbean.3 The observed preterm birth rate in North America was 11.4% of all births in
2014.4
Despite comprising a relatively low percentage of total births, more than 28% of
neonatal deaths are attributed to preterm birth worldwide.3 This accounts for more than 1
million infant deaths as a result of preterm birth. In the United States, where more than 1
in 10 births occurs preterm, preterm birth is the leading cause of infant mortality,
accounting for as much as 75% of perinatal mortality and more than half of morbidity.5
The vast majority of preterm births occur at later preterm gestational ages, with rates
increasing as gestational age increases. Approximately 20% of preterm births occur prior
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to 31 weeks gestation.1 The highest rates of morbidity and mortality occur in infants born
at the earliest gestational ages.
Maternal stress, depression, smoking, alcohol, and drug use, intrauterine
infection, and disease, both chronic and acute, have been identified as predictors of
preterm birth. Fetal health, including growth restriction, congenital malformations, and
multiple gestation also contribute to preterm birth rates. Spontaneous preterm labor is
responsible for approximately 40-45% of births, preterm premature rupture of
membranes (pPROM) another 25-30% of births, and delivery for fetal or maternal
indications accounts for the remaining 30-35% of preterm births.6 Of the approximately
13 million preterm births, up to 20% are due to hypertensive issues of pregnancy,
including over 100,000 in the United States each year.7 While it is well known that
pPROM and many preterm labors are caused by maternal infection, it has been suggested
that far more pregnancies are complicated by bacteremia than have been reported
previously.6 As many as 25-40% of preterm births are currently attributed to intrauterine
infection, with rates as high as 50% for births occurring prior to 28 weeks GA.8 In this
context, subclinical infection may contribute a pro-inflammatory uterine environment,
such that spontaneous preterm births of unknown etiology are potentially influenced by
subclinical inflammation. The earlier preterm labor occurs, the higher the frequency of
intrauterine infection, with most spontaneous births prior to 24 weeks gestation
associated with histologic chorioamnionitis, but only about 10% of those occurring at
35-36 weeks gestation.9 Histologic chorioamnionitis has been identified in 60-90% of all
preterm deliveries.10 Fetal infection, reported in 33% of fetuses with amniotic fluid
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cultures positive for bacterial infection, is also highly associated with preterm labor, fetal
and neonatal morbidity, and long term disability.11
The March of Dimes has reported annual expenses of $16.9 billion for neonatal
care, $611 million for early intervention services, and another $1.1 billion for special
education services for infants and children who are born preterm.12 A second estimate
calculated the United States national expenditure in 2005 to be $26.2 billion in medical,
educational, and lost productivity expenses.4 Preterm birth is clearly a concern in terms of
both infant morbidity and mortality, but also one which should be considered in terms of
economic impact.13

1.2. Maternal Hypertension
Hypertensive disorders of pregnancy are a significant cause of maternal and fetal
morbidity and mortality across the world. As many as 1:100 deliveries in developing
countries are complicated by eclampsia, the presence of seizures in a women with
preeclampsia, significantly contributing to high maternal mortality rates. In the developed
world, hypertensive disorders of pregnancy account for a large proportion of preterm
births. Access to medical care drives this discrepancy. Annually, over a half million
women die of pregnancy-related deaths; approximately 76,000, or 12% of these are
attributed to hypertensive issues.14 In addition, it is estimated that approximately 500,000
newborns and fetuses die due to complications of preeclampsia.15
Hypertension complicates approximately 10% of pregnancies in the United States
annually. Several separate diagnoses, including chronic hypertension, gestational
hypertension, preeclampsia, eclampsia, and HELLP syndrome are included in the overall
3

prevalence of hypertensive disorders of pregnancy.16 Preeclampsia affects 3-5% of
pregnancies and is diagnosed as new-onset hypertension and abnormal laboratory tests or
other evidence of end-organ injury occurring after 20 weeks gestation.17 It is a leading
cause of both maternal mortality and perinatal morbidity and mortality, affects an
additional 5-8% of pregnancies.19 HELLP syndrome often has rapid onset, and the
associated multi-organ involvement contributes to a high maternal mortality rate of 0.514%, and perinatal demise of between 25 and 50% of fetuses and neonates.18 There is
some debate over whether HELLP syndrome should be included in the diagnosis of
preeclampsia, or whether development follows a separate physiologic pathway which
presents similarly. With HELLP syndrome, symptoms include Hemolysis, Elevated Liver
enzymes, and Low Platelet counts, which demonstrate that the disease states has
progressed to the point of multiple system failure. Chronic hypertension is defined as
hypertension existing prior to 20 weeks gestation, and is associated with adverse
pregnancy outcomes, including IUGR, stillbirth, placental abruption, and preterm birth.
In 2004, approximately 1.7% of pregnancies were complicated by chronic hypertension.20
Chronic hypertension is associated with increased risk of developing superimposed
preeclampsia, intrauterine growth syndrome, and stillbirth, with as many as 28 out of
1,000 chronically hypertensive women experiencing a perinatal death.21
Risk factors for the development of preeclampsia include nulliparity, obesity,
extremes in maternal age, multiple gestations, diabetes, underlying chronic hypertension
or renal disease, and a family history of cardiac disorders or preeclampsia.22-25 Many
studies have addressed an underlying familial predisposition in the development of
preeclampsia.26-29 Physiologically, reduced plasma volume, increased pulse pressure, and
4

increased sympathetic response have been identified as clinical precursors to
preeclampsia and there is evidence they are altered prior to pregnancy in those who
subsequently develop preeclampsia.30 There is also strong evidence that familial
preeclampsia is associated with increased long term risk for the subsequent development
of hypertension and ischemic cardiovascular disease outside pregnancy. Women who
develop severe preeclampsia, especially early-onset, have a much higher rate of having
family members who have had early-onset cardiovascular disease of any type.31
Historically, eclampsia was recognized and described by Hippocrates over 2,500
years ago. The word “eclampsia” translates to seizures, and preeclampsia means “before
seizure.” In Hippocrates’ Coan Prognosis, the description of headaches, combined with
heaviness and seizures, were considered to be serious.32 Until the late 1700s,
preeclampsia and eclampsia were repeatedly described, but knowledge about the disease
was limited. By the mid-1800s, proteinuria and severe edema were recognized as danger
signs for the development of preeclampsia/eclampsia. It was not until the 1960s that
science began to compare preeclamptic pregnancies to normal in order to understand the
differences in order to determine causation. Since that time, there have been countless
theories about the cause of preeclampsia, however causation remains unknown.
Researchers have evaluated the possibilities of uterine ischemia, overactive inflammatory
processes, angiogenesis, prostacyclin, endothelial dysfunction, nutritional deficiency,
placental disease, hemodynamic vascular injury, preexisting maternal conditions and
physiology, immune reaction, and genetics as causes of preeclampsia.14,33,34 There is a
general consensus that placental dysfunction contributes to the development of
preeclampsia, but the definitive trigger has yet to be identified.
5

Unfortunately, as with the cause of preeclampsia, evidence about possible
treatments is also limited. Traditionally when preeclampsia was suspected or a pregnant
woman appeared to be at high risk of progressing to preeclampsia, women were placed
on bed rest, despite no evidence that restriction of movement prevents preeclampsia
development or worsening. Low-dose aspirin in early pregnancy has shown limited
effectiveness, reducing the risk of preeclampsia by only 10% in women with at least one
risk factor.14,33 The use of magnesium sulfate is well established and accepted for the
prevention of seizures, and may provide neuroprotection for neonates.16 This treatment,
while very successful at lowering blood pressure, is a muscle relaxant and increases risk
of hemorrhage following delivery.
Antihypertensive medications are often employed to prevent stroke and delay
delivery in order to optimize fetal development. Until recently, clinical guidelines
suggested immediate delivery for preeclampsia was the only option to prevent further
health issues, regardless of disease severity. Within the last decade, physicians have been
moving towards more frequent use of expectant management, including regular
monitoring and observation instead of immediate delivery at time of diagnosis. While
emergency cesarean was long considered the necessary route of delivery, there has also
been a movement toward induction of vaginal delivery, with constant blood pressure
monitoring for both mother and fetus to ensure safety during delivery. The current
protocol for delivery is to terminate pregnancies that have not reached viability whent
maternal status is life threatening and to deliver those that are over 37 weeks of
gestation.17 Between this time frame, doctors do their best to allow the fetus to mature,
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with a goal of maintaining the pregnancy until at least 34 weeks. However, if preterm
labor or other complications develop, the fetus will be delivered.
While the acute effects of preeclampsia are easier to quantify, a great deal of
current research is outlining the future health risks for both mother and offspring. The
risk of recurrence in subsequent pregnancies ranges from 20-75%, depending on severity
and stage of disease onset. Up to 20% of women whose previous pregnancy was affected
by preeclampsia go on to develop chronic hypertension or microalbuminuria. In addition,
mothers who suffer a preeclamptic pregnancy have a high rate of future cardiovascular
disease. The severity of hypertensive disease during pregnancy is also predictive of early
onset cardiovascular disease, with women who develop severe preeclampsia early in
pregnancy having the highest incidence of early-onset cardiovascular disease. Women
who develop severe preeclampsia, especially early-onset, also have a much higher rate of
having family members who have had early-onset cardiovascular disease of any type.31
Maternal hypertension is associated with adverse pregnancy outcomes including
maternal and fetal death, intrauterine growth restriction, and preterm birth.35 For preterm
infants born to hypertensive mothers, there are conflicting reports on the outcome status
of these infants. Several studies have reported that infants born to hypertensive mothers
suffer from higher rates of morbidities and developmental disability, while other studies
report the opposite effect.
Understanding maternal contributions to infant susceptibility is important, and the
association between maternal hypertension, preterm birth, and perinatal mortality, and
subsequent development of severe morbidities is not well understood.
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1.3. Infant Mortality
In 2013, the March of Dimes reported 107 deaths out of 100,000 live births occur
preterm or are classified as low birth weight.4 Improvements in perinatal survival have
been steady since the early 1990s, however infants born at the lowest gestational ages
still face high rates of morbidity and mortality.36-38 A combination of improved prenatal
and perinatal care, including surfactant and antenatal steroid therapies, have greatly
increased survival.39,40 Survival rates are highly dependent on gestational age at birth.
Lower gestational age and birth weight are attributed to higher mortality rates; 92.6% of
infants born at 22 weeks gestation, and 60.5% born at 23 weeks died in the United States,
with decreasing mortality as gestational age increased (Figure 1.1).41

Figure 1.1: Infant mortality by week gestation. Data from the Vermont Oxford Network, 2012.

Lucey et al. reported that within the Vermont Oxford Network between 1996 and
2000, 4172 infants were born with birth weights between 401 and 500 grams. The
mortality rate for these fetal infants was 83%, with high morbidity was seen in
8

survivors.42 Also using the Vermont Oxford Network Very Low Birth Weight Database,
Horbar et al. compared mortality between 2000 and 2009, reporting a decrease in overall
mortality in 501 to 1500 gram infants by 2009. Despite a reduced mortality rate, 49.2% of
all included infants and 89.2% of very low birth weight infants either died or developed
severe neonatal morbidity in 2009.43 Similar results were recently published by the
Neonatal Institute of Child Health and Human Development Neonatal Research Network,
reporting an overall decline in mortality across time, among 22+0 and 28+6 week
gestational age infants born between 2000 and 2011.44 Between 2000 and 2011, mortality
rates due to specific morbidities have changed, at least in part related to changes in
treatment. There has been a shift from morbidities related to pulmonary issues, infection,
central nervous system injury, and immaturity occurring less frequently than at previous
points in time, with an increase in necrotizing enterocolitis.44
Despite momentous improvements in perinatology over the last decades,
mortality rates in extremely preterm infants remain high.37,43,45-48 Many factors contribute
to survival, including immaturity, race, birth weight, infant sex, access to high level
medical care, and clinical course.48-53 It is becoming clear that obstetric factors also have
a large role in influencing postnatal outcome.54 As few as half of deaths in singleton
preterm infants may be due to prematurity, while the remaining factors are the result of
pathologies contributing to preterm birth, including underlying maternal infection and
disease.55 This dissertation investigates the effect of maternal hypertension on neonatal
morbidity and mortality rates.
There are conflicting reports on the effect of maternal hypertension on the
outcome of preterm infants. Deaths <12 hours after birth have been reported to be less
9

likely in infants born to hypertensive mothers, though early deaths are as much an
indication of clinical management as physiology.48 Buchbinder et al. reports that infants
born to mothers with severe gestational hypertension have lower birth weights, more
infants who are classified as small for gestational age, as well as higher preterm birth
rates at both 37 and 35 weeks when compared to women with mild preeclampsia and
those who were normotensive.56 There were no differences observed in mortality.56 This
differs from several studies reporting that hypertension in pregnancy is associated with
increased fetal, perinatal, and neonatal death.57-61 In a study of Italian infants born
between 23 to 31 weeks gestation, a marginally higher mortality (OR: 1.4, 95% CI: 1.0 to
2.0) was reported after adjustment for covariates in infants born to mothers with
“disorders of placentations,” a descriptor including growth restriction, and maternal
hypertension, when compared to those born to mothers with presumed
infection/inflammation.62 A sub-analysis, restricting inclusion to only infants with
identified maternal hypertension or clinical chorioamnionitis yielded similar overall
results, but varied by gestational age.62 They reported a gestational age dependent
relationship, demonstrating increased mortality in infants born to mothers with
hypertension prior to 28 weeks, but increased mortality in infants born to mothers with
chorioamnionitis after 28 weeks gestation.62 Other studies have found no association or
lower risk of infant mortality.63 Evans et al. reported a highly significant decrease in the
risk of infant mortality (OR=0.46, 95% CI: 0.36 to 0.50) in infants born at less than 32
weeks gestational age or with birth weights of <1500 grams in Australia and New
Zealand level III Neonatal Intensive Care Units.17 In 2006, Chen reported reduced early
and late neonatal mortality when comparing infants born to mothers with hypertension to
10

those born to normotensive mothers in both early preterm (OR= 0.59, 95% CI: 0.56 to
0.63) and late preterm infants (OR= 0.80, 95% CI: 0.73 to 0.87), but an increased risk of
mortality in term infants (OR= 1.08, 95% CI: 1.02 to 1.14) born to mothers with
hypertension.64 Similarly, Bastek reported lower mortality in infants born to mothers with
hypertension when born at low gestational ages, but increased risk in term infants.65
Two arguments have been presented to explain the mechanism in which maternal
hypertension may result in lower mortality risk. The first suggests that hypertension in
pregnancy encourages fetal development in the face of uteroplacental dysfunction by
allowing for improved fetal nutrition in the presence of increased uteroplacental blood
flow.68 The second argument suggests that it is not the “protective” effect of
hypertension, but the deleterious effects of the “other” etiologies of preterm birth which
increases risk of serious morbidities, including periventricular leukomalacia and
intraventricular hemorrhage. Many factors contribute to infant development, both in utero
and after delivery, and these all play a role in mortality risk and potential for morbidities
to occur. While preterm birth itself is a risk factor for infant mortality and morbidity, the
interplay between maternal and fetal factors, both pre- and post-natal, as well as those
occurring due to medical practice, all influence outcome (Table 1.2). Hwever, the
important take away message of this dissertation is not that infants born to hypertensive
mothers have lower rates of mortality than other infants, but that mechanistically, there
are likely other factors, including underlying maternal infection and inflammation, which
acts mechanistically to worsen outcomes for infants’born following a spontaneous
preterm birth.
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Figure 2.2: Contributors to Preterm Birth, Infant Morbidity and Mortality.

Part of this discrepancy also comes from defining maternal hypertension. Some
studies only compare preeclampsia to normotensive mothers while some combine
multiple diagnoses. Another reason for the variation is due to statistical approach and
selection of covariates. A 2011 Italian study of infants reported differences in preterm
delivery rates by hypertension diagnosis, with 21.2% of women with preeclampsia
delivering very preterm, 37.2% born to mothers with chronic hypertension with
superimposed hypertension, and lower rates to women with chronic hypertension (7.8%)
and gestational hypertension (5.9%), and only 1.2% of normotensive women delivering
very preterm.66 Regional differences in ability and willingness to treat extremely preterm
infants also play a role in risk of mortality. 51,67
12

1.4. Morbidity
Similar to the debate regarding the risk of mortality, there have been varying
reports of the importance of maternal hypertension on the risk of morbidity in preterm
infants born to mothers with hypertension. As preterm birth rates have risen, survival has
increased due to technological advances and collaborative medical efforts to improve
care—such as through the Vermont Oxford Network. Prior to assisted ventilation in the
1970s, very few infants born prior to 28 weeks gestation survived. Assisted ventilation,
postnatal surfactant, administration of antenatal corticosteroids, and increased use of
neonatal intensive care have resulted in improvement of survival rates.50,69 In recent
years, improvements in neonatal care have reduced the rate of severe morbidity in
survivors from 46.4% to 41.4% between 2000 and 2009, however the impact of
extremely early births remain high, both for individual outcomes and societal costs
incurred.37,43 Extremely preterm infants are at high risk of injury to their undeveloped
organs. Serious morbidity occurs to the neonatal brain, through intraventricular
hemorrhage (IVH) and periventricular leukomalacia (PVL); eyes, in the form of
retinopathy of prematurity (ROP); and lungs, due to acute respiratory distress syndrome
or chronic lung injury (CLD). Maternal infections, resulting in pPROM and preterm labor
as etiologies for preterm birth, have been associated with early onset sepsis, IVH,
respiratory dysfunction, and development of NEC in preterm infants.70,71
Intraventricular hemorrhage (IVH) is a hemorrhage into the germinal matrix
tissues. It is associated with neonatal seizures, periventricular leukomalacia, increased
intracranial pressure, and post-hemorrhagic hydrocephalus.72 IVH is classified into
13

stages, with grade 1 composing blood in the germinal matrix, grade 2 being blood in the
lateral ventricle without ventricular distention, grade 3 including ventricular distention,
and grade 4 involving the parenchymal space. Grade is inversely associated with
gestational age.73 PVL often occurs with IVH, and is a white matter injury, characterized
by infarction and necrosis, often occurring after a decrease in cerebral blood flow.72
Diagnosis for both are made following cranial ultrasound or computed tomography, and
the highest risk for IVH occurs in the first week of life.
Many morbidities, including PVL, have been linked to fetal exposure to infection
and/or inflammation. One study suggested that vaginal delivery was associated with
increased risk of IVH and PVL, but that vaginal deliveries may be a proxy for maternal
infection/inflammation due to a higher rate of cesarean sections in iatrogenic deliveries,
and vaginal deliveries following pPROM and spontaneous preterm labor.74 Similar
results were reported by Vergani et al., who noted that in non-iatrogenic births of less
than 32 weeks, a higher risk of IVH was noted in infants showing signs of placental
infection on pathology.75 Verma et al. also reported an increase in IVH and PVL in 500
to 1750 gram infants born following pPROM and preterm labor in comparison to
medically indicated deliveries. They reported that 33% of infants born following
pPROM, 38.9% of those born following preterm labor, and 17.7% of infants born after
physician indicated births developed IVH.76 More severe IVH, grades 3 and 4, have been
found to be associated with early sepsis and a lack of antenatal steroids in comparison to
matched controls in infants less than 1500 grams. 77 Gagliardi specifically looked at the
association with maternal hypertension, IVH and PVL in infants born prior to 31 weeks
gestation and reported a decreased risk of severe IVH and PVL in mothers with
14

hypertension compared to those without and mothers with chorioamnionitis.62,78 A
similar population based study of 22 to 29 week infants in France also demonstrated
decreased risk of IVH and PVL in infants born to hypertensive mothers when compared
to those born after pPROM.79
Retinopathy of prematurity (ROP) is a significant cause of blindness due to
reduced angiogenesis in the eyes of preterm infants. ROP is a disease with 2 phases, the
first being a period of hyperoxia with reduction of vascular endothelial growth factor
(VEGF) and followed by a period of relative hypoxia with an upregularion of VEGF and
increased angiogenesis. It is attributed to exposure of the immature retina to high oxygen
levels. ROP is diagnosed in stages, with stage I having mildly abnormal blood vessel
growth, stage II having moderate abnormal growth, stage III with severe abnormal
growth, and stage IV presenting with a partially detached retina.80 The main risk factors
include low gestational age at birth, low birth weight, receiving supplemental oxygen
therapy.81,82 Postnatal weight gain also serves as a reliable predictive aid in determining
risk in infants born prior to 30 weeks gestation or at less than 1500 grams birth weight.83
Interestingly, both maternal aspirin therapy during pregnancy—which is used for
prevention of preeclampsia, and exposure to in utero infection/inflammation are also
considered risk factors. Studies comparing extremely preterm infants report increased
risk of ROP in infants born to mothers with disorders of placentation (including
preeclampsia and growth restriction) compared to those born following
chorioamnionitis.9 Restricting analyses to infants born to mothers with hypertension also
demonstrates increased risk of severe ROP when compared to infants born after
presumed infection/inflammation.62,78
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Necrotizing enterocolitis (NEC) is inflammatory disease of the small intestine,
leading to necrosis of the bowel. It occurs in between 1 and 8% of patients in the neonatal
intensive care unit.84 The specific pathogenesis is not understood, though the biggest risk
factors are prematurity and low birth weight. It has been proposed that increased rates of
cesarean sections may contribute by preventing exposure to vaginal flora.85 Symptoms
include abdominal distention, gastrointestinal bleeding, and pneumatosis intestinalis.
Severe NEC also includes air in the portal vein or pneumoperitoneum following intestinal
perforation. While NEC usually occurs in the first two weeks of life, it has a high
mortality rate, with 18% of infants with mild NEC, 21% of those with moderate NEC,
and 62% of those with severe NEC, dying from the condition.84 Rates of NEC have been
increasing, but this is primarily due to improved neonatal care improving survival and
allowing for subsequent morbidities to develop. Up to 90% of infants that develop NEC
would have died prior to development if not for advanced neonatal practices.84 NEC rates
decrease with increasing gestational age, however the proportion of deaths due to NEC
rises as gestational age increases.86
Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease (CLD)
resulting from lung damage caused by mechanical ventilation, including high oxygen
exposure, positive pressure ventilation, or poor bronchial drainage following intubation.87
In severe cases, it requires long term use of oxygen and lifelong breathing problems.
Infants receiving oxygen supplementation at 36 weeks postmenstrual age or 34 weeks
postmenstrual age if discharged with oxygen are considered to have CLD.88 There is
some evidence that the inciting factors that cause CLD may begin prior to birth as a result
of systemic inflammatory response in utero.89 BPD is most common in infants born at the
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lowest gestational ages and those with birth weights less than 1000 grams—the infants
with the most immature lungs who rely exclusively on assisted ventilation, with as many
as 77% of these infants being diagnosed.87 BPD was reported to occur more frequently in
infants born prior to 28 weeks gestation to mothers with intrauterine vascular disorders
(including preeclampsia), with 29% of these infants, compared to 11% of those born
following spontaneous preterm labor.90 Gagliardi also reported increased risk for BPD in
extremely preterm infants born to mothers with hypertension and other disorders of
placentation compared to those with infection/inflammation or clinical
chorioamnionitis.62,78
Infections are another major cause of morbidity in extremely preterm infants.
These are classified as early and late, depending on whether the infection occurred prior
to or after 72 hours of life. Early sepsis is rare due to prenatal identification of Group B
Streptococcus and chemophylaxis at delivery, with less than 2% of very low birth weight
infants being diagnosed. Identification of specific bacterial infections identify group Bstreptococcal infections and Escherichia coli. Late sepsis is more common, affecting as
many as 25% of extremely preterm infants, in large part due to extended NICU stays
resulting in more time for exposure.91 These infections are mostly due to gram positive
coagulase-negative staphylococci. Infections are inversely linked to BW and GA with
high morbidity and mortality, with a higher percentage of deaths occurring with increased
gestational age.91 Risk of early sepsis is lower in infants born to mothers with
hypertension compared to those born to mothers with chorioamnionitis.62
The development of each individual, as well as a combination of multiple
morbidities are associated with poor prognosis, particularly in infants who are born the
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smallest and earliest. Half of surviving extremely preterm birth suffered severe neonatal
morbidities.92 The development of major morbidity in very low birth weight infants who
survive to hospital discharge ranges from 83% of 501 to 750 gram infants to 18.7% of
1251 to 1500 gram infants.43 Combined assessment scores for predicting outcome of
infants who develop one or more morbidities have shown promise in prognosis. Schmidt
scores have been validated in extremely low birth weight infants of 500 to 999 grams,
using a simple count of BPD, brain injury, and severe ROP. While each morbidity
individually correlated an odds ratio of 2.4 to 3.7 for poor outcome at 18 months
corrected age, a simple count revealed a predictive values of poor outcome at 18%, 42%,
62%, and 88% with 0 to 3 of these morbidities occuring.93 The inclusion of NEC and
infection within this model slightly increased the ability to predict poor outcomes at 18
months.94 Being able to confidently predict future prognosis is important for both clinical
practice and counseling of families facing difficult decisions regarding infants born
extremely preterm. The NICHD maintains an online calculator for predicting outcome
using variables available at time of birth.95 However clinical course clearly plays a role in
determining survival and future health. Predictive methods for calculating how
morbidities impact long term outcomes are inexact in extremely preterm infants, and yet
it is imperative that prognoses be reevaluated as clinical course progresses.96 Each
morbidity carries its own risks, both for survival and long term outcome.

1.5. Growth Restriction and Small for Gestational Age
Small for gestational age (SGA) infants are defined as those being within the
lowest 10th percentile for birth weight corrected for gestational age. These infants may be
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small due to a variety of factors, including genetic, however many SGA infants are small
due to growth restriction in utero. Maternal, fetal, and placental factors all play an
important role in optimizing—or compromising—growth potential. Infants who fail to
meet their potential have the highest risk of increased mortality and morbidities when
compared to appropriately grown infants.97,98 Intrauterine growth restriction (IUGR), the
fetal identification of delayed growth maturation, is a phenotype resulting from many
underlying factors, but is commonly cited as the single largest contributing factor to
perinatal mortality in otherwise healthy fetuses.99 Growth restriction has an attributable
cause in only about 40% of cases. Most identifiable causes include abnormalities in
uteroplacental perfusion, fetoplacental perfusion, and abnormal villous structure at the
fetal maternal interface.100 IUGR infants are classified by symmetricallity. Symmetrically
growth restricted infants make up 20 to 30% of growth restriction, while asymmetric
growth restriction is observed in the remaining 70 to 80%.101 Symmetrical growth
restriction is believed to occur early in development, and includes reduced measures of
all biometrical measures of fetal growth. This type of growth restriction is more
commonly associated with fetal malformations and early exposure to infections such as
cytomegalovirus.102 As many as 20% of fetuses with recognized intrauterine growth
restriction have chromosomal abnormalities or malformations.102,103 Asymmetric growth
restriction typically has later onset with head sparing and decreased abdominal
circumference, indicating a reduction in adipose tissue deposit but more normal brain
development. Asymmetric growth restriction is associated with utero-placental
insufficiency seen in cases of preeclampsia and maternal hypertension, as well as
maternal malnutrition.101,102
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Due to the high incidence of mortality in the presence of malformations or
chromosomal abnormalities, these infants are frequently excluded from studies
examining morbidity and mortality in IUGR and SGA infants. Within otherwise healthy
low birth weight infants, perinatal mortality in SGA infants is approximately 3-fold
higher than that of appropriately grown infants.104-106 SGA infants born at the lowest
gestational ages and who have the lowest birth weights have the highest risk of poor
prognosis when compared to appropriately grown infants.104,107,108 The greater the degree
of growth restriction, as evidenced by birth weights of less than the 3rd percentile, the
higher morbidity and mortality. 109 These infants have an 8-fold increased risk of
mortality when compared to infants within the 25-75th percentiles.52 Growth restriction is
considered to be the largest independent predictor of mortality. Multiple studies of
stillbirth demonstrate stillborn infants have higher degrees of growth restriction, as
evidenced by smaller weight for gestational age, compared to live born SGA infants. 110113

Surviving SGA infants have repeatedly been shown to have poorer outcomes,

demonstrated by higher rates of assisted ventilation, BPD, and CLD when compared to
appropriately grown infants.98,104,114
SGA and IUGR frequently occur in the presence of maternal hypertension.
Preeclampsia and chronic hypertension are recognized risk factors for IUGR and
SGA.74,108,113,115,116 Compared to normotensive mothers, risk of SGA is dependent on
diagnosis, with an increase of 1.5-fold for mild preeclampsia, 3.2-fold in the presence of
severe preeclampsia, and a 2.5-fold increase with chronic hypertension.113 It has been
suggested that IUGR is a symptom of preeclampsia, linking growth restriction to disease
severity.117
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Observed rates of SGA in the presence of hypertension differ with gestational
age. The SCOPE study, studying SGA infants born at all gestational ages between 2004
and 2008, reported 10.7% occurred in the presence of maternal hypertension.112 This
association changes in the preterm population, with more SGA seen in hypertensive
mothers at lower gestational ages. Within a population of 24 to 31 week infants, 75% of
SGA infants were born to hypertensive mothers, and half of those in the 10th to 25th
percentile.118 Similarly, Chen et al. reported 21.5% of infants born to mothers with
hypertension prior to 32 weeks were identified as SGA, while only 5.9% of infants born
to mothers without hypertension were SGA.64 Preterm, infants born after PE are 10-25%
smaller than their peers of similar GA.119
Mortality rates for these infants varied greatly, with 10% for SGA infants born to
mothers with hypertension, and 23% for those without hypertension.64 Mortality rates of
46% lower have been reported for preterm singleton SGA infants born to mothers with
hypertension compared to other SGA infants.52 Other studies have not found this
association, and report no difference in mortality or morbidity rates in the presence and
absence of maternal hypertension.120

Multiple explanations for why it appears SGA infants have lower mortality when
born to mothers with hypertension when compared to other SGA infants have been
suggested. One explanation is that growth restriction in the presence of maternal
hypertension encourages fetal lung maturation, resulting in better survival after
delivery.121 More likely, improved accuracy in dating pregnancies, and thus determining
gestational age at time of birth, has improved knowledge of appropriate maturity level.
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Historically, larger infants were presumed to be older, and thus expected to be at a higher
developmental maturity.122 However, in the presence of growth restriction, infants who
are identical in terms of birth weight can have differing gestational ages. In this situation,
the infant who is more developmentally mature would be expected to have a better
outcome, despite being growth restricted.

1.6. Long Term Outcomes
It is well established that severe neonatal morbidity is associated with an
increased risk of neurodevelopmental and physical delay.123-129 Most neonatal predictors
associated with improved survival are also associated with an increased chance of
survival free of major sensorineural disability.123 Morbidities most often linked to long
term delay are bronchopulmonary dysplasia (or chronic lung disease), major brain injury,
necrotizing entercolitis, nosocomial infections, and retinopathy of prematurity 124-127.
Necrotizing enterocolitis (NEC) affects 1 to 8% of NICU patients and is also linked with
poor neurodevelopmental outcome.128,129
Disability rates as high as 65% were reported in infants born <29 weeks gestation
in the mid-1980s. Mortality prior to discharge and severe morbidity in VLBW infants
decreased substantially from 2000 to 2009; a high proportion of extremely preterm
infants still develop 1 or more severe morbidities, which are associated with long term
neurodevelopmental or physical delay.43 Despite a decrease in the most severe disabilities
in infants born <28 week GA in 2005 43,124, 59.1% of extremely preterm infants are
diagnosed with some level of disability at 2 years of age.130 Severe disability is defined as
a major neurologic abnormality, such as cerebral palsy, unilateral or bilateral blindness,
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deafness requiring hearing aids, or cognitive functioning less than 2 standard deviations
below the mean on cognitive assessments. The majority of infants who develop delay
have mild impairment without cerebral palsy or neurosensory impairments.125 More
importantly, special outpatient services are utilized by 54.7% of infants born <28 weeks
GA by 18 to 22 months.131
The relationship between maternal HTN and long term outcome is also complex,
with several studies reporting a negative association in infant outcome at follow-up, and
an equal number reporting a positive association. For instance, Grether et al. and Murphy
et al. both report a reduced rate of cerebral palsy seen in children who were born
extremely preterm.132,133 Alternatively, increased rates of cerebral palsy were reported by
Hagberg and Jonas in infants born to mothers with pregnancies complicated by
HTN.134,135 A case-control study by Gray et al. reports infants born 24 to 32 weeks GA
have lower risk of cerebral palsy and no increased risk of cognitive impairment.136
Randolph et al. examined the National Institute of Child Health and Development very
low birth weight (VLBW) database, and reported 32% decreased risk of death or
neurodevelopmental impairment in infants born to hypertensive mothers.137 For cognitive
delay, there are similarly conflicting reports, with some studies citing a higher incidence
of neurodevelopmental problems in extremely preterm infants born to mothers with
preeclampsia or HTN, and some studies reporting lower risk of neonatal and NICU
mortality as well as less cognitive impairment at 2-year follow-up in extremely preterm
infants born in the Netherlands.138-142. While the majority of studies focus on early
follow-up at 18 to 24 months corrected age, some studies have also evaluated longer term
follow-up. Evaluation of movement and cognitive performance at 1 year predicts follow23

up at 4 years in infants born <1000g.143 2-year neurodevelopmental assessment has been
reported to be a good predictor of school-age ability; abnormal 2-year disability and
delay accurately predict the need for special education services at age 5 to 6.144 In
addition, preterm birth is associated with lower cognitive scores and increased risk of
attention deficit hyperactivity disorder compared to term controls at age 5.145

1.7. Clinical Decision Making and Ethics
With delivery being the only “cure” for preeclampsia, families can find
themselves facing a heartbreaking decision—do they wait to see if the disease state
progresses, risking maternal life, or do they terminate or induce to save the mother, but
risk the fetus? When preeclampsia occurs before twenty-two weeks or after thirty-seven
weeks of gestation, the answers are straightforward. Before twenty-two weeks, and the
fetus’ chance of survival is nil, while after thirty-seven weeks, the fetus, barring other
complications, will adapt well to extrauterine life. However, infants born between
twenty-three weeks and thirty-seven weeks face many obstacles and survival is often
dictated by the availability of a high-level neonatal intensive care unit and quality care.
Often when a pregnant woman initially presents with hypertension, she can be
managed with anti-hypertensives and inpatient monitoring for worsening symptoms. This
often buys additional time for the fetus to develop, antenatal steroids to be administered,
and for patients to be transferred to tertiary care facilities with high-level neonatal
intensive care units prior to delivery. Randomization to expectant management in early
onset preeclampsia cases has been shown to delay delivery by an average of 15 to 24
days for mothers diagnosed prior to 25 weeks gestational age, and by 9.5 days for those
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diagnosed between 25 and 34 weeks gestational age.146 Expectant management does
result in increased maternal morbidity, including development of HELLP and
eclampsia.146 Barring severe maternal disease, delaying delivery can greatly improve
neonatal outcome. Maternal anti-hypertensives can frequently control blood pressure well
beyond the needed 12-24 hours to administer corticosteroids. Alternatively, other causes
of delivery, such as clinical chorioamnionitis, pPROM, or premature labor do not always
allow obstetricians the time to weigh multiple options prior to delivering.
Regional differences also exist in attitudes about offering aggressing treatment at
the lowest gestational ages—the periviable at 22 and 23 weeks gestational age. A study
comparing proactive management and selective management in regions of Sweden found
proactive management to be associated with improved survival without increased
neonatal morbidity.147 There are large variations in infant mortality rates between
countries, across regions within countries, and also between different racial and ethnic
groups.67 The MOSAIC cohort study of European births occurring prior to 32 weeks
gestation demonstrated mortality rates as high as 18-20% in the Netherlands and Poland,
compared to rates of 7-9% in Germany and the United Kingdom, where aggressive
treatment is common.148,149
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CHAPTER 2: THE EFFECT OF MATERNAL HYPERTENSION ON
MORTALITY IN INFANTS 22 TO 29 WEEKS GESTATION

2.1. Abstract

Objective: To evaluate the effect of maternal hypertension on mortality risk, prior to
discharge, in infants 22+0 to 29+6 weeks gestational age (GA).
Methods: We evaluated 88,275 North American infants whose births were recorded in
Vermont Oxford Network centers between 2008 and 2011 Infants born between 22+0 and
29+6 weeks GA were evaluated in 2-week GA cohorts, and followed until death or
discharge. Logistic regression was used to adjust for birth weight, antenatal steroid
exposure, infant sex, maternal race, inborn/outborn, prenatal care and birth year.
Results: 21,896 infants were born to hypertensive mothers; 13% died prior to NICU
discharge compared to 20% of the 66,379 infants not associated with hypertension.
Infants associated with maternal hypertension had significantly lower mortality, after
adjusting for other characteristics, than preterm infants not born to hypertensive mothers,
at all GAs examined as follows: 22/23: OR 0.65 [95% CI 0.55 to 0.77]; 24/25: OR 0.77
[95% CI 0.71 to 0.84]; 26/27: OR 0.66 [95% CI 0.59 to 0.74; 28/29: OR 0.58 [95% CI
0.51 to 0.67]. Additionally, births associated with maternal hypertension increase
dramatically by GA, resulting in a larger proportion of births associated with maternal
hypertension at later GAs.
Conclusions: Preterm birth due to any cause carries significant risk of mortality,
especially at the earliest of viable GAs. Maternal hypertension independently influences
mortality, with lower odds of mortality seen in infants born to hypertensive mothers, after
adjustment, and should be taken into consideration prior to counseling parents.
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2.2. Introduction
Neonatal mortality in the very low birth weight (VLBW) population, defined as
those with birth weights of less than 1500 grams, has declined considerably in the early
1990s, but has since leveled off, while birth rates within this population have increased
from 9% in 1981 to 12.5% in 2004.1-5 Declines in neonatal mortality rates have been
attributed to improvements in perinatal care and prenatal monitoring, including
widespread use of surfactant and antenatal steroid therapies.6,7 However, infants born at
the lowest gestational ages (GA) still face high rates of mortality and serious morbidities,
often with life-long health problems stemming from preterm birth.8-10 Between 2000 and
2009, 49.2% of infants recorded in the Vermont Oxford Network (VON) who were born
at birth weight (BW) of 501 to 1500 grams, died or suffered a severe neonatal
morbidity.11 In the United States, the preterm delivery rate is 12-13%; the vast majority
of these occur at the latest of preterm GAs. Approximately 20% of preterm births occur
prior to 31 weeks gestation.4 Both lower GA and lower BW are associated with higher
mortality rates with survival occurring in 2-35% of newborns at 23 weeks, 17-62% at 24
weeks, and 35-72% at 25 weeks.12,13
Hypertension, including diagnoses of chronic hypertension, gestational
hypertension, preeclampsia, eclampsia, and HELLP syndrome (hemolysis, elevated liver
enzymes, and low platelets), complicates 6-8% of pregnancies in the United States.14
Chronic hypertension, defined as hypertension existing prior to 20 weeks gestation, is
associated with adverse pregnancy outcomes including intrauterine growth restriction
(IUGR), stillbirth, placental abruption, and premature birth. In 2004, approximately 1.7%
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of pregnancies were complicated by chronic hypertension.15 Women with chronic
hypertension are at an 8-fold higher risk of developing superimposed preeclampsia
compared to the general population, and were at least twice as likely to experience
adverse neonatal outcomes.16 Preeclampsia, characterized by new onset high blood
pressure and abnormal laboratory tests, develops after 20 weeks gestation and is a leading
cause of both maternal mortality and perinatal morbidity and mortality, affects an
additional 5-8% of pregnancies.17 Whether maternal hypertension affects outcome in
preterm infants is debated, with some studies stating hypertension in pregnancy is
associated with an increased risk of mortality, while other studies suggest either no
association or a decreased risk.18-24
We examined the hypothesis that infants born to mothers with hypertension will
have a lower mortality rate, after adjusting for maternal and perinatal covariates, than
infants who are not delivered in association with maternal hypertension. Preterm births
are attributed to a short list of causes: spontaneous preterm labor (40-45% of births),
preterm premature rupture of membranes (pPROM) (25-30% of births), or delivery for
fetal or maternal indications (30-35%), where maternal hypertension is a leading cause.25
pPROM and many preterm labors are associated with maternal infection. Infection causes
a pro-inflammatory cytokine cascade that is implicated as a major contributor to toxic
uterine environments, with implications on both short-term survival and long term
impairment.26-30 As many as 25-40% of preterm births are attributed to intrauterine
infection, particularly those manifesting as spontaneous preterm labor and pPROM, with
rates as high as 50% for births occurring prior to 28 weeks GA.31 In this context,
subclinical infection may often contribute a pro-inflammatory uterine environment, such
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that preterm births of unknown etiology are potentially influenced by subclinical
inflammation. Alternatively, maternal hypertension results in a different form of
proinflammatory environment, one we hypothesize to be less detrimental to infant
survival.

2.3. Methods
Infants born at GA 22+0 to 29+6 were identified as a part of the VON VLBW
database. The VLBW database is a data repository, begun in 1990, in which all reporting
centers within the VON submit observational clinical care and outcome data for infants
born in or transferred to member centers, between 401 and 1500 grams, or between 22+0
and 29+6 weeks GA.32 Beginning in 2008, the first obstetric factors, including
dichotomous variables for maternal hypertension and diagnosis of chorioamnionitis were
collected.33 For this reason, births occurring during calendar years 2008 through 2011
were examined. Inclusion was limited to infants born in the 667 North American centers.
Infants from multiple gestations were excluded as multiple gestation is both a risk factor
for preterm birth, and are specifically associated with increased risk of maternal
hypertension, likely due to different maternal physiologic adaptations specific to
pregnancy of multiple gestations. As mortality was our primary outcome of interest,
infants with chromosomal abnormalities and birth defects with associated high rates of
mortality were excluded as their inclusion (n=4288) would have artificially inflated our
mortality rates.34 The University of Vermont Institutional Review Board approved the
database for research purposes.
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The VON database defines maternal hypertension as a single reading above 140
systolic or 90 diastolic, prior to or during, the pregnancy that is identified in the maternal
medical record at the time of delivery presentation. These cases may or may not have had
other diagnostic criteria of preeclampsia, such as proteinuria or other end-organ
involvement. Chronic hypertension is not differentiated from hypertensive disorders
specific to pregnancy. Mortality is defined as death prior to discharge. Infants who were
born in VON centers are classified as inborn. Those born elsewhere and transferred to a
VON reporting center within the first 28 days of life are classified as outborn. All
transferred infants are tracked for survival status until final discharge. Antenatal steroid
administration is coded when dosing was administered at any time prior to delivery, with
no differentiation in the database between a single dose and full course of treatment.
Prenatal care refers to documentation of any prenatal visits.
Initial demographic characteristics examined differences between infants born to
hypertensive mothers versus infants born to non-hypertensive mothers using chi square
tests and t-tests. GA cohorts were created in 2-week increments: 22/23, 24/25, 26/27, and
28/29 to account for differences in developmental maturity and obstetric management
practices with advancing gestation. Observed mortality rates between infants born to
mothers with and without hypertension were compared within each GA cohort. Logistic
regression was used to estimate the independent effect of hypertension on infant
mortality. Additional covariates in the model were infant sex, maternal race,
inborn/outborn status, antenatal steroid exposure, prenatal care, and birth weight. These
covariates were chosen due to their association with outcomes and prior inclusion in
VON models. Standardized rates of mortality were computed based on the derived
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logistic regression model. These estimates represent the rates that would be observed in
infants born to hypertensive mothers and the comparison group if the two groups had
identical covariate distributions equivalent to the population used to derive the model. All
regression analyses were based on generalized estimating equations (GEE) that accounted
for the clustering of infants within hospital.35 Odds ratios are reported with 95%
confidence intervals (CI). All analyses were performed using SAS Statistical Software
Version 9.3 (SAS Institute, Cary, NC) with statistical significance determined using α=
0.05.

2.4. Results
Infants identified from the VON VLWB database as having been born between
22+0 and 29+6 weeks GA between 2008 and 2011 yielded a study population of 88,275
infants. They were evenly distributed by birth year. Across GA however, the population
was skewed toward more mature infants, as evidenced by higher GA, with 3.2% of births
occurring at 22 weeks, 7.1% at 23 weeks, 11.3% at 24 weeks, 12.4% at 25 weeks, 13.7%
at 26 weeks, 15.6% at 27 weeks, 17.7% at 28 weeks, and 19.1% at 28 weeks. Infants born
to hypertensive mothers included 21,896 infants, approximately 25% of the total, with a
similar trend seen within the rates increasing with increasing GA (Figure 2.1).
Infants born to hypertensive mothers were significantly smaller than infants born
to non-hypertensive mothers in all GA cohorts. (22/23: mean HTN = 500.1 ± 124.6,-HTN
= 558.4 ± 98.7 grams; 24/25: HTN = 605.4 ± 163.0, -HTN = 732.8 ± 134.4; 26/27: 785.8
± 186.1, -HTN = 967.5 ± 181.4; 28/29: HTN = 1040.3 ± 226.3, 1244.8 ± 232.2 grams (all
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p’s < .001). They were more likely to be inborn, born by cesarean section, be small for
gestational age, and have received antenatal steroids (Table 2.1).
Univariate analyses indicated odds of mortality for HTN relative to other causes
as being GA dependent, with a reduced rate of mortality at 22/23 weeks (OR 0.82, 95%
CI: 0.71 to 0.97), increased risk of mortality at 24/25 weeks (OR 1.26, 95% CI: 1.17 to
1.36), increased risk at 26/27 (OR 1.10, 95% CI: 1.00 to 0.20), and reduced odds at 28/29
weeks (OR 0.88, 95% CI 0.77 to 0.99). Delivery room deaths accounted for 54.6% of
deaths at 22/23 week, 10.9% of 24/25 week, 6.1% of 26/27 week, and 6.4% of 28/29
week infants. Adjusting by birth weight alone resulted in a reduced odds estimate of
mortality at all GAs (Table 2.2).
Multivariate analysis allowed for a more complete risk assessment adjusting for
the many factors known to contribute to neonatal mortality: birth weight, infant sex,
maternal race, inborn/outborn, antenatal steroids, and prenatal care. Significantly reduced
standardized rates of mortality were observed at all GAs in association with maternal
hypertension as an independent variable; within the 22/23 cohort, mortality was 64.4% of
infants born to hypertensive mothers, while 71.8% of those in the comparison group died
(OR 0.64, 95% CI 0.53 to 0.76). In the 24/25 week cohort, mortality rates were lower;
23.3% of infants exposed to hypertension and 27.8% of other infants (OR 0.75, 95% CI
0.69 to 0.82]). Mortality at 26/27 weeks was 7.7% in infants exposed to hypertension and
11.0% in the remaining infants (OR 0.65, 95% CI 0.59 to 0.75). The most mature group,
28/29 weeks, had the lowest mortality rates, at 2.8% for the group of interest and 4.6% of
comparison infants (OR 0.60, 95% CI 0.52 to 0.70).
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2.5. Discussion
There are conflicting reports on the effect of maternal hypertension on the
outcome of preterm infants. We report here that infant mortality is decreased at all
gestational ages for those born to mothers with hypertension when compared to other
infants. Several studies have reported hypertension in pregnancy is associated with
increased fetal, perinatal, and neonatal death.18,20-23 Others report no association or
decreased risk of mortality.19 Chen et al. examined early neonatal, late neonatal, and
postneonatal death in infants born to hypertensive mothers, compared to infants from
non-hypertension associated pregnancies. Mortality was lower in infants born between 24
and 31 weeks GA, who were exposed to maternal hypertension than similar infants who
were not born from hypertension-associated pregnancies, (OR 0.38, 95% CI 0.34 to
0.42).36 Randolph et al. examined the National Institute of Child Health and
Development VLBW database, and reported a 32% decreased risk of
death/neurodevelopmental impairment in infants born to hypertensive mothers.37
Population based Australian and New Zealand Neonatal Network, reported infants born
prior to 29 weeks gestation to have odds ratio of 0.68 (95% CI: 0.52 to 0.90) in the
presence of maternal hypertension when compared to other infants.18 Similarly, Gagliardi
et al. reported a lower GA at birth, and higher risk of mortality in infants, 23-31 weeks
gestation, who were born to mothers with infection and/or inflammation than those born
to hypertensive mothers.38 Conflicting results appear to be attributable to differences in
statistical approach as the choice of covariates can result in differing conclusions. Our
univariate analyses demonstrated a gestational-age dependent effect of maternal
hypertension on mortality, but correcting for maternal race, infant sex, BW, antenatal
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steroids, prenatal care, and inborn/outborn status, revealed a decreased risk of mortality at
all GAs examined. BW had the strongest influence on mortality rates. Following
adjustment, all GA cohorts had lower odds of mortality in infants born to hypertensive
mothers.
Despite improvements in perinatal-neonatal medicine, mortality rates in
extremely preterm infants remain high. Extremely preterm births are most commonly
attributed to spontaneous preterm labor, pPROM, or delivery for maternal or fetal
indicators. In each of these situations, obstetric factors have greatly influenced postnatal
outcome through intrauterine environment and maternal health. In considering maternal
hypertension, two arguments have been presented to explain the mechanism through
which hypertension influences fetal development. The first suggests hypertension in
pregnancy encourages improved fetal maturation in the presence of reduced
uteroplacental blood flow and increased intrauterine stress.39 The second argument
suggests that many other causes of preterm birth, not related to hypertension, are linked
to infection and inflammation, where the proinflammatory cytokine cascade associated
with these infections increases risk of serious morbidities, including periventricular
leukomalacia (PVL) and intraventricular hemorrhage (IVH). Von Dadelszen et al.
attributed higher observable SNAP-II scores, lower rates of PVL and IVH, and increased
survival in SGA infants born to hypertensive mothers, to a combination lack of exposure
to infection and a higher developmental maturity at birth.39 While the VON VLBW
database attempts to capture data pertaining to the presence of infection and/or
inflammation by including a variable for chorioamnionitis, initial evaluation of this
variable led us to determine the data captured is a poor representation as diagnosis often
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is determined from pathologic review or culture, and is unlikely to be reported in infant
charts due to time elapsed between birth and the return of results. Additionally, many
cases are likely subclinical, and therefore not recorded as such in the maternal record.
Given our findings and previous supporting literature, one potential interpretation
of the data presented is that infants born to hypertensive mothers have lower rates of
mortality when compared to other infants due to the lack of underlying maternal
disorders that worsen the outcomes of infants who are exposed to a pro-inflammatory
uterine environment.
One limitation of the current study lies in VON’s definition of hypertension. By
including all cases in which mothers had the identification of a singular blood pressure
reading of 140 mmHg systolic or 90 mmHg diastolic in the maternal record, the
incidence of maternal disease could be overestimated. The VON definition also does not
discriminate between chronic and pregnancy associated hypertensive diagnoses. In a
comparison of births between women with gestational hypertension and those with
preeclampsia, both were associated with increased perinatal morbidity and mortality
compared to pregnancies not complicated by hypertension.40 However, Buchbinder et al.
reported higher rates of preterm delivery and more SGA infants born to women with
severe gestational hypertension than to those with mild preeclampsia, demonstrating that
particular diagnoses are not indicative of disease severity and fetal effect.41 Also, as
chronic hypertension is also associated with increased risk of developing superimposed
preeclampsia, intrauterine growth syndrome, and stillbirth, the inability to differentiate
specific diagnoses may not be crucial.42
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We see a higher rate of inborn infants born to hypertensive mothers compared to
those outborn. This is understandable, as one factor that differentiates maternal
hypertension from other causes of birth is the issue of expectant care. Often when a
pregnant woman initially presents with hypertension, she can be managed with antihypertensive agents and both maternal and fetal monitoring for worsening symptoms.
Alternatively, other causes of delivery, such as clinical chorioamnionitis, pPROM, or
premature labor may not allow adequate time for appropriate transfer of care. A review of
studies utilizing randomization of expectant management in early onset preeclampsia
cases reports mean delays in delivery of an average of 15.4-24 days (<25 weeks GA at
diagnosis) and 9.5 days (25-34 weeks GA). This likely increases the likelihood of
mothers receiving, and clinical effect seen, with a full course of antenatal steroids, though
the VON VLBW database does not differentiate between a single dose and full course.
Mortality in extremely preterm infants also reflects variations in practice
management, parental decision-making, and clinical ethics. The majority of deaths are
due to immaturity, there are also clinical policies on aggressive resuscitation that are ill
defined for the lowest GAs. Though the MOSAIC study focuses on European-born
infants, it is highly likely their results are transferrable to regional variations within the
United States. These include a high level of variability in center-specific willingness to
aggressively treat infants born on the cusp of viability (<25 weeks), and likely factor into
the high mortality rates seen at the lowest GAs.43,44
Most studies evaluate infants by birth weight, allowing for comparisons between
infants of similar size; this may misclassify infants by GA. Birth weight traditionally was
used because it is an available and accurate measure, yet is a proxy for both maturity and
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growth.45 As we report, infants born 22+0 to 29+6 weeks GA to hypertensive mothers
are, on average, born at increased GA, but with smaller birth weight than their
counterparts. Omission of birth weight from our logistic models resulted in projected
ORs of 1.51 (1.39 to 1.63) and 1.29 (1.16 to 1.44) at GAs of 24/25 and 26/27,
respectively. There were no significant differences in outcome according to maternal
hypertension within 22/23 or 28/29 week cohorts. While birth weight and GA are
typically closely correlated, both GA and birth weight are clinically significant
independent measures of variability, accounting for the majority of mortality. Similar
findings have been previously reported.18,46 Preterm infants born from pregnancies
complicated by preeclampsia measure 10-25% smaller than similar gestational aged
infants born from pregnancies without hypertension, and are 3-4 times more likely to be
SGA.20 Given the distribution of hypertension within the population, it is likely that even
within our 2-week GA cohorts, infants born to hypertensive mothers are slightly older,
and therefore more mature, than comparable infants.
Maternal well-being greatly impacts infant health; the importance of maternal
factors have recently received a great deal of attention. Within our population, we see a
skew toward more births at later preterm GAs, leading us to believe reasons for early
delivery vary across GA, and as such, our findings are somewhat attributable to a
heterogeneous maternal comparison group. As we demonstrated, the composition of our
population changes as GA increases, and a greater number of later-gestation aged infants
are born to mothers with hypertension. This reflects a “control” population that is likely
also changing, either to reflect subclinical infection, or other idiopathic etiologies. We
unfortunately lack the ability to examine other maternal factors, such as socioeconomic
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status, alcohol use, smoking status, and the initiation of prenatal care; all variables that
have implications in terms of understanding how maternal factors influence preterm
infant outcome.
Factors at birth, including infant sex, exposure to antenatal steroids, GA and
birth weight are the strongest indicators of survival at the time of birth, however many
postnatal measures also predict survival. Ambalavanan et al. reports the importance of
using adaptable models to reevaluate outcome prediction as clinical information becomes
available.47 While our model predicts mortality rates, it utilizes covariates that are
available at the time of birth, and thus does not factor the effect of subsequent morbidity
on mortality rates. In clinical practice, it is important to recognize how clinical course,
particularly the development of severe morbidities, can drastically change infants’
projected outcome.

2.6. Conclusion
Understanding the contribution of maternal hypertension on mortality in VLBW
infants will aid obstetricians and neonatologists in counseling parents, and could
influence clinical decision making in provision of early intervention for infants on the
cusp of viability. For deliveries prior to 30 weeks, risk of morbidity and mortality are
high, with a strong association between GA at birth and rate of survival. However, if an
infant is born between 22+0 and 29+6 weeks gestation, to a mother with hypertension,
that infant faces decreased odds of mortality than similar infants born to mothers
without hypertension. We believe this association is likely due to differences in
intrauterine environment.
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Table 2.1: Demographic information by maternal hypertension status.

Inborn Location*
Cesarean Delivery*
Prenatal Care*
Male Sex*
Race*
Black
White
Hispanic
Other
Birth weight (grams)*
Small for Gestational
Age*
Gestational Age (weeks)*
Antenatal Steroids*
1 minute Apgar*

No
Hypertension
(66,379)
81 %
52 %
94 %
55 %

Hypertension
(21,896)
90 %
89 %
97 %
48 %

31.7 %
40.8 %
21.2 %
6.4 %
949 (308)

36.3 %
41.2 %
17.3 %
5.1 %
863 (271)

4%

20 %

26.2 (2.1)
72 %
4.6 (2.5)

27.0 (1.8)
85 %
4.7 (2.5)

Data are presented as percentage or population mean ± SD. An * identifies a significant difference between
groups, p < .05.
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Figure 2.1: Distribution of infants born by gestational age and hypertension status, in raw numbers
and as a percentage of each gestational age population.
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CHAPTER 3: SURVIVING INFANTS BORN BETWEEN 22+0 AND 29+6
WEEKS GESTATION HAVE DECREASED MAJOR MORBIDITY WHEN
BORN OF HYPERTENSIVE MOTHERS

3.1. Abstract
Extremely preterm infants have high rates of morbidity; complications that are
linked with long term disability and neurodevelopmental delay. The association between
maternal hypertension and early morbidity is unclear.
We evaluated 72,016 infants born 22+0 to 29+6 weeks GA, in North American
Vermont Oxford Network centers, 2008-2011 for the effect of maternal hypertension
(HTN) on risk of morbidity prior to discharge in infants 22+0 to 29+6 weeks gestational
age (GA). All survived to NICU discharge and were analyzed for development of severe
morbidity during their NICU stay. Morbidities included chronic lung disease (CLD),
intraventricular hemorrhage grades 3-4 (IVH), cystic periventricular leukomalacia (PVL),
retinopathy of prematurity grades 3-5 (ROP), necrotizing entercolitis grades >2 (NEC),
infection, and a combined risk scores. Rates were compared between HTN and -HTN
within 2-week GA cohorts. Logistic regression was used to adjust, within cohorts, for
birth weight, antenatal steroid exposure, infant sex, maternal race, location, prenatal care
and birth year. Odds ratios are reported with 95% confidence intervals.
Infants born at lower GAs had higher rates of all morbidities. Rates of HTN
increased with GA. HTN infants were smaller (mean 863±271 vs. 949±308 grams;
p<.01), yet older (mean 27.0±1.8 vs. 26.2±2.1 wks GA; p<.01). After adjustment,
surviving HTN infants exhibited fewer serious morbidities and were less likely to have
≥2 serious morbidities than -HTN infants across all GAs.
Surviving preterm infants born prior to 30 weeks gestation have high rates of
severe morbidity. Infants born to mothers with hypertension have decreased risk of
developing severe morbidity than comparison infants. This may translate to a reduced
risk of long term developmental delay. Understanding how maternal hypertension
influences outcome can aid in counseling families of extremely preterm infants.
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3.2. Introduction
Infants born at extremely low gestational ages, below 30 weeks gestation, have
high rates of mortality and morbidity. Although survival has improved, the smallest of
these infants still have very high rates of morbidity and subsequent severe developmental
delay.1 These births and follow-up care prove costly. In 2005 alone, $26.2 billion were
spent on costs associated with preterm births occurring prior to 36 weeks gestation in the
United States.2 In addition burdens due to emotional strain and lost wages associated with
high demands for ongoing care weigh heavily on caregivers and families of children with
disabilities.3
The majority of preterm births have been attributed to two categories of causation,
disorders of placentation, including preeclampsia and intrauterine growth restriction, or
inflammation, including preterm labor, preterm premature rupture of membranes
(pPROM), placental abruption, and cervical insufficiency.4,5
Maternal hypertension complicates approximately 10% of pregnancies, and is
associated with adverse pregnancy outcomes including maternal and fetal death,
intrauterine growth restriction, and preterm birth.6 For preterm infants born to
hypertensive mothers, there are conflicting reports on the outcome status of these infants.
Several studies have reported that infants born to hypertensive mothers suffer from higher
rates of morbidity and developmental disability, while other studies report the opposite
effect.7,8 Over the past 2 decades, rates of preeclampsia have increased by 25%, as such,
understanding the effect of hypertension on fetal development and infant outcome is
essential.9

59

It is well established that some neonatal morbidities are associated with an
increased risk of neurodevelopmental and physical delay. The specific morbidities most
often linked to long term delay include bronchopulmonary dysplasia or chronic lung
disease (CLD), major brain injury, nosocomial infections, necrotizing enterocolitis
(NEC), and retinopathy of prematurity (ROP).10-15 The greater the number of individual
morbidities suffered, and the more severe their presentation, the higher the risk of long
term developmental impact. Combined risk assessment scores have been used to
demonstrate that the additive effect of key morbidities including bronchopulmonary
dysplasia, major brain injury, and severe retinopathy of maturity, yield a predictive 18%,
42%, 62%, and 88% rate, respectively, of presence of neurodevelopmental disability at
18 months corrected age in infants born under 1000 grams.16
Extremely preterm birth rates have increased in the past decade. While
improvements in neonatal care over the past decade have reduced the rate of severe
morbidity in survivors from 46.4% to 41.4%, the impact of extremely early births remain
high, both for individual outcomes and the societal costs incurred.1,17. Maternal
hypertension is one maternal complication contributing to extremely preterm birth.
Extremely preterm infants born to hypertensive mothers have lower rates of mortality
than infants not born to hypertensive mothers.18 Understanding maternal contributions to
infant susceptibility is important, and the association between maternal hypertension and
subsequent development of severe morbidities is not well understood. While maternal
hypertension is unmistakably a serious maternal condition, we hypothesize that it has a
less detrimental effect on fetal development and subsequent neonatal outcome than other
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etiologies contributing to extreme prematurity, and will result in fewer serious
morbidities during neonatal intensive care unit (NICU) stay.

3.3. Methods
Infants were identified from the Vermont Oxford Network (VON) Very Low
Birth Weight (VLBW) database. The VON VLBW database collects de-identified data
using predetermined definitions and uniform reporting forms across all participating
member centers.19 The University of Vermont Institutional Review Board approved the
VON VLBW database for research purposes. Infants included in the VLBW database
must have a birth weight 401 and 1500 grams or born at gestational ages 22+0 to 29+6
and either inborn or transferred to a VON member center. The inclusion of maternal
hypertension in the database limited our analysis to 2008 to 2011. In this analysis, infants
were included if they were born between 22+0 and 29+6 weeks gestation, from singleton
gestation, inborn or transferred within 28 days of birth to one of the 667 North American
VON member centers, between 2008 to 2011, and survived until discharge from the
NICU. Infants with life threatening birth defects (n=2099) were excluded from analysis.20
Maternal hypertension is defined as a single reading above 140 systolic or 90
diastolic, prior to or during the pregnancy and identified in the maternal medical record at
the time of delivery presentation. Infants born in VON centers are classified as inborn
while those born elsewhere and transferred within the first 28 days of life are classified as
outborn. All transferred infants are tracked for survival status until final discharge.
Antenatal steroid administration is coded as yes if dosing was administered at any time
prior to delivery. Prenatal care refers to documentation of any prenatal visits.
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Infants were identified as having a morbidity if they were diagnosed with severe
interventricular hemorrhage (IVH), periventricular leukomalacia (PVL), severe ROP,
NEC, CLD, or infection. Severe IVH was defined as grades 3 and 4, and cases were
identified using cranial ultrasound, MRI, or computed tomography scan within 28 days of
birth.21 PVL diagnosis required the presence of periventricular cysts on similar imaging
techniques. Severe ROP was classified as stages ≥3.22 The absence of retinal examination
was recorded as an absence of ROP. NEC was identified by one or more clinical
characteristics and one or more radiographic finding. CLD classified as receiving oxygen
supplementation at 36 weeks postmenstrual age or if discharged with oxygen prior to 34
weeks postmenstrual age.23 For infants discharged prior, presence of oxygen use at
discharge confirmed a diagnosis. Infections, including early bacterial sepsis within 3 days
of birth, late bacterial infections identified as coagulase-negative Staphylococcus, fungal,
nosocomial, or other bacterial infections diagnosed more than 3 days after birth were
evaluated individually and are reported as an overall risk of infection.
Morbidity was also evaluated using combined risk assessments modified from
Schmidt et al, as an indicator of projected long term disability and neurodevelopmental
delay.16 These combined risk assessment scores using a simple count of brain injury,
including both IVH and PVL, bronchopulmonary dysplasia, and severe ROP as markers
of injury which have a high predictive level on outcomes at 18 months corrected age.16
Combined risk assessment scores based on Schmidt were dichotomized ≤1 vs ≥ 2 in order
to identify risk for long term disability of greater than 50%.
Comparisons were made between surviving infants born to hypertensive mothers
versus those born to non-hypertensive mothers using chi-square tests and t-tests, with
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statistical significance accepted at α=.05 (Table 3.1). Infants were analyzed in 2-week
gestational age increments: 22/23, 24/25, 26/27, and 28/29, to account for differences in
developmental maturity and obstetric management practices with advancing gestation.
Comparisons within GA cohorts were also performed. Each morbidity was analyzed
separately, using logistic regression modeling to estimate the independent effect of
hypertension. A variable combining risk of any severe morbidity was similarly evaluated.
Combined risk assessments of less than or equal to 1 or greater than or equal to 2 were
also evaluated. For all models, infant sex, maternal race, inborn/outborn, antenatal steroid
exposure, prenatal care, and birth weight were included as covariates. These covariates
were selected due to their association with outcomes and prior inclusion in VON
models.1,24 Odds ratios are reported with 95% confidence intervals (CI). Standardized
rates of morbidity were computed based on the derived logistic regression model. These
estimates represent the rates that would be observed in infants born to hypertensive
mothers and the comparison group if the two groups had identical covariate distributions
equivalent to the population used to derive the model. Regression analyses were based on
generalized estimating equations (GEE) that accounted for the clustering of infants within
hospital.25 All analyses were performed using SAS Statistical Software Version 9.3 (SAS
Institute, Cary, NC).

3.4. Results
The VON VLWB database contains records from 92,472 singleton infants born
between 2008 and 2011. Chromosomal abnormalities and birth defects occurred in 4288
infants who were excluded from analysis. Death occurred in 15,853 infants. An
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additional 315 infants were excluded due to missing survival data. Of the 72,016 infants
identified as surviving to hospital discharge, 26% were born to mothers with
hypertension. Births as a percentage of the population increased with increasing GA, with
3.6% of all infants born at 22/23 weeks, 21.1% at 24/25, 32.2% at 26/24, and 43.1% at
28/29 weeks gestation. We also observed increasing rates of maternal hypertension with
increased GA, composing 10.2% of the overall population at 22/23 weeks, 17.6% at
24/25, 26.5% at 26/27, and 31.8% of the population at 28/29 weeks.
The study population was racially diverse, with 41% Caucasian, 32% Black, 20%
Hispanic, and 6% classified as Other. There were more male infants, composing 53% of
the study population, but the majority of infants, 53%, born to hypertensive mothers were
female. While the majority of infants were inborn, received antenatal steroids, and
prenatal care, rates for each were higher for those born to hypertensive mothers (Table
3.1).
At all GAs, infants born to hypertensive mothers were smaller than comparison
infants. Within the 23/24 GA week cohort, there was an 8% discrepancy in size, 15% at
24/25 weeks, 18% at 26/27, and 16% within the 28/29 week cohort. Alternatively, the
infants of hypertensive mothers were also older in terms of GA, with the mean GA of
infants born to hypertensive mothers being 27.3 weeks while comparison infants were
born at mean 26.7 weeks.
One or more severe morbidities were seen in 52.8% of surviving infants. Infants
born within the lower week GA cohorts, 22/23 and 24/25, had higher rates of all
morbidities, with 93% of 22/23 week, 82% of 24/25, 57% of 26/27, and 32% of 28/29
week infants developing at least one morbidity. Unadjusted risk for any morbidity was
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higher in infants born at greater than 24 weeks gestation when born to hypertensive
mothers (Table 3.2). After adjustment for birthweight (Table 3.3), infants born after 24
weeks gestation had decreased risk of developing any severe morbidity when born to
hypertensive mothers. Fully adjusted odds ratios, with corresponding 95% confidence
intervals (95% CI), and standardized rates are presented for each morbidity in Table 3.4.
CLD was observed most frequently, in 36.0% of surviving infants. Prior to
adjustment, infants born to hypertensive mothers had higher rates of CLD when born at
GAs above 24 weeks. There were no differences in the 22/23 week cohort, with more
than 75% of each group developing CLD. After adjustment, infants born between 22 and
27 weeks did not differ between groups, however those in the 28/29 week cohort had
lower odds (OR: 0.88 95% CI: 0.82 to 0.95) of developing CLD when born to
hypertensive mothers.
Infections were second most frequently occurring, in 19.7% of survivors. Prior
to adjustment, infants born to mothers with hypertension had no difference in risk of
developing infection when born at 22 to 25 weeks. For those born between 26 and 29
weeks, risk was increased in infants born to hypertensive mothers. After adjustment,
there was no difference in risk for 22/23 or 28/29 week infants and risk was decreased in
24/25 and 26/27 week infants born to hypertensive mothers.
ROP (9.4%), severe IVH (8.2%), NEC (7.0%), and PVL (3.5%) were observed
in fewer infants. Infants born to hypertensive mothers had a lower risk of developing
severe IVH at all GA in both univariate and multivariable models, the other morbidities
were more complex. For each, ROP, NEC, and PVL, results were GA dependent, with a
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reductions in risk seen within the higher GA infants born to hypertensive mothers (Table
3.4).
Combined risk assessment, assessing risk of developing ≥2 severe morbidities,
resulted in no univariate differences risk to infants born to hypertensive mothers at GAs
at less than 28 weeks. Within the 28/29 week cohort, only 1% of infants attained a
combined risk assessment score of ≥2, however there was a statistically significant
decrease in risk for infants born to hypertensive mothers (OR: 0.82 95% CI: 0.70 to
0.97). After adjustment, there was no difference in risk between groups for 22/23 week
infants, however all other infants had reduced risk of developing ≥2 severe morbidities
when born to hypertensive mothers.

3.5. Discussion
Maternal health plays an important role in determining infant outcomes. In our
study, after adjustment, infants born to hypertensive mothers had significantly lower odds
of developing IVH within any gestational age cohort, PVL or ROP after 24 weeks
gestation, NEC at 24/25 and 28/29, any infection at 24 to 27 weeks GA, CLD at 28/29,
and an overall decreased risk of developing any severe morbidity when born after 24
weeks gestation. For no morbidity evaluated was maternal hypertension independently
associated with an increased risk of morbidity. Similarly to some other reports, we report
infants born to hypertensive mothers had a higher GA and better outcomes than
comparison infants.4 These findings conflict with some studies which suggest infants
born to hypertensive mothers have decreased risk of IVH and PVL, but increased risk of
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other morbidities. In a recent population based study by Gagliardi et al, 23-31 week
Italian infants born to mothers with disorders of placentation surviving NICU discharge
had lower risk of IVH and PVL but higher risk of BPD and ROP than infants born
following chorioamnionitis.4 A similar population based study of 22 to 29 week infants in
France also demonstrated decreased risk of IVH and PVL in infants born to hypertensive
mothers when compared to those born after pPROM.26 Maternal infections, most
typically linked to pPROM and preterm labor as etiologies for preterm birth, have been
associated with IVH, respiratory dysfunction, and development of NEC in preterm
infants.27,28
The driving predictor of morbidity was birth weight, with adjustment for birth
weight alone leading to a “flip” in odds ratio, from increased risk associated with
maternal hypertension to a decreased risk in CLD, ROP, and infection after 24 weeks. By
including other known predictors of morbidity in a fully adjusted model, including infant
sex, maternal race/ethnicity, inborn/outborn status, prenatal care, and antenatal steroids,
odds ratios continued to predict lower risk of all serious morbidities. The inclusion of
other predictors caused odds ratios to be slightly higher than when adjusting for birth
weight alone. This supports prior studies reporting increased risk of morbidity and
mortality in small for gestational age infants.29-31 Bernstein et al. reported increased risk
of NEC and respiratory distress syndrome in growth restricted very-low-birth-weight
infants.30 These findings mimic our results in that prior to adjustment, CLD and NEC
rates were higher in our infants born to mothers with hypertension (who were smaller),
but adjustment for birth weight resulted in decreased risk for both morbidities.
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The occurrence of morbidities stems from immaturity of infants’ developing
organ systems. IVH and PVL often occur together, with combined injury associated with
high rates of cerebral palsy and low developmental scores.32 Our results highlight
reduced risks across all GAs and of similar magnitudes in severe ROP, severe IVH, and
PVL, which may be indicative of a related pathway between these morbidities. CLD,
brain injury, and severe ROP are independently associated with poor developmental
outcome during childhood, including low Bayley II scores, cerebral palsy, and
neurodevelopmental disabilities.
Predictive methods for calculating how morbidities impact long term outcomes
are inexact in extremely preterm infants. Schmidt’s combined risk assessment scores
have been validated in extremely low birth weight infants of 500 to 999 grams, using a
simple count of BPD, brain injury, and severe ROP. While each morbidity individually
yielded an odds ratio of 2.4 to 3.7 for poor outcome at 18 months corrected age, a simple
count revealed predictive values of poor outcome at 18%, 42%, 62%, and 88% with 0 to
3 of these morbidities occuring.16 Adding additional unique morbidities, including NEC
and infection within this model slightly increased the ability to predict poor outcomes at
18 months.33 While this system is validated only in infants 500 to 999 grams, we elected
to include infants outside of this BW window as the majority of infants beyond this range
were within the 28/29 week GA cohort, and thus at a lower risk of developing severe
morbidity. The benefit of combined risk assessment scores is the potential for revised
later life projections of disability based on clinical progress of individual infants. This
allows for more comprehensive clinical counseling to parents in regards to outcome.
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We report higher rates of 0 and 1 and lower rates of 2 or more morbidities in
infants born to hypertensive mothers when using combined risk assessments in our
overall population. Within cohorts, rates of ≤1 or ≥2 morbidities are similar with and
without maternal hypertension, and prior to adjusting for other covariates. After
adjustment, all GA cohorts have significantly lower risk of developing ≥2 serious
morbidities. Combined risk assessments suggest the development of severe morbidity is
an effective measure of long term outcome. Using this logic, it is likely that extremely
low gestational age infants born to hypertensive mothers have better long term outcomes
than comparison infants due to their reduced risk of developing CLD, IVH, PVL, ROP,
and NEC.
While this study has many strengths, the foremost being the size of this large
multi-center database, it also suffers from limitations associated with definitions within
the database. The VON database uses a very pragmatic definition of maternal
hypertension, accepting either a singular systolic reading over 140 mmHg or a singular
diastolic reading over 90 mmHg as maternal hypertension. This prevents us from
exploring differences between hypertension diagnoses, so our results likely reflect some
degree of obstetric management in cases where pregnancies can be prolonged. However,
risk factors for and outcomes of infants born to each category are similar, so we believe it
is unlikely that further parsing definitions would change our results.34 Additionally,
chronic hypertension, while a recognized contributor to fetal growth restriction, is only
observed in approximately 2% of pregnant women, and thus is unlikely to compose much
of our hypertension population.

69

It is important to address the selection of covariates as prior to adjustment, infants
born to hypertensive mothers appeared to have increased risk of developing CLD, severe
ROP, infections, and a combined 1 or more morbidity. Our covariates—BW, infant sex,
maternal race/ethnicity, antenatal steroids, prenatal care, and location of birth are all well
accepted by other models and reported in NICHD and prior VON publications.1,35 GA
and BW are the two greatest predictors of outcomes at time of birth, and as BWs were
significantly lower in infants born to hypertensive mothers as opposed to comparison
infants, we viewed the decision to include BW within GA cohorts as crucial to
understanding the independent contributions of hypertension to established models. In
addition, by stratifying our population by gestational age, we have a better predictor of
development than studies which use birth weight to define their population. Historically,
birth weight was easily available and presumed to be the best predictor of fetal
development. However the common use of ultrasound for pregnancy dating has resulting
in gestational age being a much more accurate representative measure of fetal
development—especially with the extremely preterm population, where fetal growth
restriction is commonly reflected in low birth weights. We attribute the disagreement in
results from prior publications to statistical approach.
The birth weight paradox has been addressed in prior publications.36-38 In this
paradox, the association between prenatal variables and postnatal outcomes may result in
collider bias when the adjusted variable may have been affected by a causal relationship
between the two variables. That raises the question of whether birth weight is a proxy for
fetal development. In order to determine if our findings were the result of collider bias,
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we also modeled BW corrected for GA in order to minimize this potential bias, and
conclusions were the same as correcting for BW within GA windows.
Maternal hypertension can lead to preterm birth, as well as fetal growth
restriction, which both impact morbidity. These interactions could potentially result in
collider bias. However, other factors also result in preterm birth and growth restriction.
Our understanding of intrauterine exposure to infection and inflammation is
evolving. We project inflammation associated with infection, even when subclinical, has
a more detrimental effect on fetal development than that associated with hypertension.
Recent studies outline ways in which infants born after exposure to different uterine
environments have different outcome projections.39-41 Hypertension in pregnancy, while a
serious condition that threatens both mother and fetus, seems to have a less detrimental
effect on fetal/neonatal development than that associated with alternate processes leading
to preterm birth. After adjustment, infants born to hypertensive mothers have decreased
risk of developing IVH, PVL, or ROP, as well as lower rates of CLD, NEC, and
infections. In addition, they have lower combined risk assessments, which have been
validated as a method of evaluating risk of long term delay. These findings are important
for clinical management, long term projections of development risk and health care
needs, as well as counseling of parents of NICU infants.42-48
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Table 3.1: Infant demographics and maternal characteristics for infants born to
mothers with and without hypertension.
No
Hypertension
Hypertension
(18,963)
(53,053)
80.5
90.4
Inborn*
54.6
89.8
Cesarean Delivery*
94.1
96.6
Prenatal Care*
54.3
47.4
Male Sex*
Race*
31.3
35.5
Black
41.3
41.9
White
20.9
17.4
Hispanic
6.5
5.2
Other
1016 ± 285
901 ± 257
Birth weight, Grams
(mean ± SD)*
22/23 weeks*
605 ± 89
558 ± 101
24/25 weeks*
749 ± 131
635 ± 163
26/27 weeks*
977 ± 175
800 ± 180
28/29 weeks*
1250 ± 226
1046 ± 222
Gestational Age,
27.1 ± 1.8
27.7 ± 1.6
Weeks (mean ± SD)*
77.8
87.1
Antenatal Steroids*
Individual characteristics marked with an asterisk are significantly different between groups (p <.05).
Tabled values represent percent unless otherwise indicated.
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CHAPTER 4: MATERNAL HYPERTENSION AND MORTALITY IN SMALL
FOR GESTATIONAL AGE 22+0 TO 29+6 WEEK INFANTS

4.1. Abstract
Infants born prior to 30 weeks gestational age (GA) to mothers with
hypertension (HTN) have lower rates of mortality and serious morbidities when corrected
for maternal and infant characteristics, including birth weight. Given the association
between growth restriction and maternal HTN, we sought to determine if small for
gestational age (SGA) infants, (birth weight <10th percentile for GA), have a similar
decreased risk of mortality when born to mothers with HTN.
We identified 6,897 singleton SGA, 22+0 to 29+6 week GA infants born
between 2008 and 2011 and cared for at 578 North American centers in the Vermont
Oxford Network. Singleton infants with chromosomal abnormalities and birth defects
were excluded. SGA was defined by 2001 & 2002 US national statistics, accounting for
sex and race/ethnicity. Mortality rates were compared between the 4,317 born to mothers
with HTN and 2,580 comparison infants. Logistic regression was used to adjust for BW,
infant sex, maternal race, inborn/outborn, antenatal steroid exposure, prenatal care and
GA. Data are presented as mean±SD. Odds ratios (OR) are reported with associated 95%
confidence intervals (CI).
SGA HTN infants were older (mean 26.9±1.9 vs. 26.6±2.2 weeks; p<.001) than
comparison SGA infants. There were no significant differences in BW (HTN: 584±159
vs -HTN: 562±156 grams; p=.27). Death occurred in 29% of SGA HTN infants and 43%
of comparison infants. Univariate analyses revealed lower mortality for SGA HTN
infants (OR 0.54, 95% CI: 0.48 to 0.60). After adjustment, mortality remained lower in
the SGA HTN group when compared to other SGA infants (OR=0.60, CI: 0.52 to 0.69).
Extremely preterm SGA infants face exceedingly high rates of mortality. Although
maternal HTN is associated with SGA, SGA infants born to mothers with HTN have
decreased risk of mortality compared to SGA infants born to mothers without HTN, after
adjustment for antenatal and maternal characteristics. This finding is important for
parental counseling and, we speculate, the result of detrimental physiologic effects
associated with alternative mechanisms for fetal growth restriction.
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4.2. Introduction
Small for gestational age (SGA) infants have increased mortality when
compared to appropriately grown infants (AGA).1 SGA infants are most commonly
defined as those being within the lowest 10th percentile birth weight for a given
gestational age. A variety of factors, including genetic, maternal, fetal, and placental
health play a role in determining growth potential; infants who fail to meet their potential
have the highest risk of increased mortality and morbidities. Intrauterine growth
restriction (IUGR), the fetal identification of delayed growth maturation, is commonly
cited as the single largest contributing factor to perinatal mortality in otherwise healthy
fetuses.2 Infants born preterm are more frequently identified as growth restricted in
comparison to term infants.3 The cause of IUGR is identifiable in approximately 40% of
pregnancies, but remains idiopathic in the majority of cases. Most identifiable causes
include abnormalities in uteroplacental perfusion and, fetoplacental perfusion.4
Within the United States, 12-13% of infants are born preterm, before 37 weeks
gestation.5 Infants categorized as extremely preterm, under 32 weeks gestation, compose
52.7% of overall infant mortality, yet include only 1.9% of 2013 United States live
births.6 While only 10% of infants are regularly identified as being SGA, the incidence of
delayed growth is significantly higher in preterm infants, with up as many as 30% of low
birth weight preterm babies with birth weights which would meet criteria for IUGR if
they had remained in utero.7 These infants face an increased risk of perinatal mortality of
4 to 10 times that of AGA infants and preterm infants identified as SGA have a reported
13.8 times increased risk of death within the first year of life.8
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Maternal hypertension has been consistently associated with the identification of
IUGR, with as many as 59% of infants born to women with severe early onset
preeclampsia being classified as growth restricted.9 In terms of SGA, there is a 3-4 fold
increase in risk in women with preeclampsia compared to those without.10 Chronic
hypertension is associated with the greatest incidence of low birth weight when compared
to normotensive women or to those with hypertension developing during pregnancy.10,11
In the preterm population, infants born to a mother with preeclampsia, a subset of those
developing hypertension during pregnancy, are on average 10-25% smaller than
comparison infants of a similar gestational age.12
We have previously reported that infants born prior to 30 weeks gestation have a
decreased risk of mortality when born to hypertensive mothers, as compared to similar
weight infants born to normotensive mothers.13 Given the clear associations between
maternal hypertension and growth restriction, and increased mortality in the preterm SGA
population, we sought to determine if this association holds in an SGA population, with
SGA infants born to hypertensive mothers having a decreased risk of mortality when
compared to SGA infants born to normotensive mothers.

4.3. Materials and Methods
Small for gestational age infants born between 22+0 and 29+6 weeks gestational
age were identified as a part of the VON VLBW database. To be included in the VLBW
database, infants must have been born either between 401 and 1500 grams, or between
22+0 and 29+6 weeks GA.14 We examined mortality in infants born in the years 2008 to
2011 due to the availability of obstetric data, including maternal hypertension status.
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Inclusion was limited to infants born in the 667 North American centers. Infants from
multiple gestations and those with chromosomal abnormalities and birth defects
associated high rates of mortality were excluded. The VLBW database exists in deidentified form, and as such, the University of Vermont Institutional Review Board has
deemed it exempt from review.
Small for gestational age infants were identified using the 2001 & 2002 US
national statistics, accounting for gestational age, infant sex and maternal race/ethnicity.15
Maternal HTN was categorized dichotomously from maternal medical records at the time
of delivery presentation, with the presence of a single reading above 140 systolic or 90
diastolic, prior to or during pregnancy defining hypertensive status. Infants born in VON
reporting centers are classified as inborn. Those born elsewhere and transferred to a VON
reporting center within the first 28 days of life are classified as outborn. Antenatal steroid
administration is defined as dosing administered at any time prior to delivery, with no
differentiation in the database between a single dose, full course or multiple courses of
treatment. Prenatal care refers to documentation of any prenatal visits. Mortality was
defined as death prior to discharge. All transferred infants are tracked for survival status
until final discharge.
Mortality rates were compared between the 4,317 SGA infants born to mothers
with HTN and the 2,580 comparison SGA infants. Initial demographic characteristics
evaluated differences between infants born to hypertensive mothers versus infants born to
non-hypertensive mothers using chi2 square and t-tests. Observed mortality rates between
infants born to mothers with and without hypertension were compared within the total
population and within 2-week increments: 22/23, 24/25, 26/27, and 28/29 to account for
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differences in developmental maturity and obstetric management practices with
advancing gestation. Logistic regression was used to estimate the independent effect of
hypertension on infant mortality. Additional covariates in the model were birth weight,
infant sex, maternal race, inborn/outborn status, antenatal steroid exposure, prenatal care,
and gestational age. These covariates were chosen due to their association with outcomes
and prior inclusion in VON models.1,16 Standardized rates of mortality were computed
based on the derived logistic regression model. These estimates represent the rates that
would be observed in infants born to hypertensive mothers and the comparison group if
the two groups had identical covariate distributions equivalent to the population used to
derive the model. All regression analyses were based on generalized estimating equations
(GEE) that accounted for the clustering of infants within hospital.17 Odds ratios are
reported with 95% confidence intervals (CI). All analyses were performed using SAS
Statistical Software Version 9.3 (SAS Institute, Cary, NC) with statistical significance
determined using α=.05.

4.4. Results
Small for gestational age infants accounted for 6897 (7.9%) births recorded
within the VON VLBW database between 2008 and 2011. Fewer infants were classified
as SGA at 22 weeks gestation, however rates were fairly consistent from 23 to 29 weeks
gestation (Figure 4.1). SGA infants born to hypertensive mothers were more likely to be
inborn, and delivered by cesarean (Table 4.1). There was an overrepresentation of
African American/Black male infants in the hypertension group, however the rate of male
births was markedly lower (52.8%) in HTN SGA than comparison SGA infants (60.4%).
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The hypertension group received higher rates of prenatal care and were more likely to
have received antenatal steroids than comparison infants. They were also born at a
slightly higher gestational age (mean 26.9 ± 1.9 vs. 26.6 ± 2.2 weeks; p<.001). The
infants born to mothers with hypertension had slightly higher birth weights than
comparison infants (HTN: 584 ± 159 vs -HTN: 562± 156 grams; p<.001).
Mortality was high within our SGA population, with death occurring prior to
NICU discharge in 29% of SGA infants born to hypertensive mothers and 43% of
comparison infants. Mortality rates decreased with increasing gestational age in both
groups, however remained higher in infants born to mothers without hypertension within
all gestational age windows (Figure 4.2). Univariate analyses demonstrated markedly
lower mortality for SGA HTN infants with an odds ratio of 0.54 (95% CI: 0.48 to 0.60).
After adjustment for clinically relevant variables, mortality remained lower in the SGA
HTN group when compared to other SGA infants (OR=0.60, CI: 0.52 to 0.69). Other
variables contributing to the mortality model included birth weight (OR=0.45 per 100
grams, CI: 0.41 to 0.49), male sex (OR= 1.91, CI: 1.68 to 2.17), antenatal steroids (OR=
0.45, CI: 0.38 to 0.54), gestational age (OR=0.82 per week, CI: 0.78 to 0.87), and race
other than black (Hispanic OR=0.86, CI: 0.68 to 1.09; Caucasian OR=0.78, CI:0.68 to
0.91; Other OR=0.75, CI: 0.57 to 0.99). These results are presented in Table 4.2.
Within 2-week gestational age cohorts, the greatest reductions in mortality
relating to maternal hypertension were seen at the lowest gestational ages. Infants born to
mothers with HTN had significantly lower mortality than comparison infants in all
cohorts born prior to 28 weeks GA (Table 4.3; 22/23: OR 0.23, CI: 0.12 to 0.45; 24/25:
OR 0.68, CI: 0.53 to 0.88; 26/27: OR 0.57, CI: 0.46 to 0.70). For infants born at 28/29
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weeks gestation, there was no significant relationship between maternal hypertension and
mortality (OR 0.78, CI: 0.59 to 1.03).

4.5. Discussion
As expected, we report SGA infants in both groups have high rates of mortality,
with decreases seen with increasing gestational age. Preterm infants born on the lower
end of the growth curve face much higher odds of mortality compared to AGA infants,
regardless of pregnancy complications.18,19 Multiples studies have reported preterm SGA
infants face a 3-fold increase in mortality compared to non-SGA infants of similar
gestational age.1,20 Our results demonstrate that while infants classified as SGA face high
rates of mortality, there are population subsets, including those born to mothers with
hypertension, who have decreased risk when compared to other SGA infants. This effect
is seen in all infants born prior to 30 weeks gestation with the greatest effect at the lowest
gestational ages at time of birth.
Several studies have suggested that maternal hypertension is associated with
decreased survival in SGA infants, however many of these studies do not restrict to the
preterm population. By restricting population to preterm infants, mortality in SGA infants
born to hypertensive mothers is decreased when compared to normotensive mothers.
Chen reported that preterm SGA infants born to mothers with hypertension have lower
risk of mortality but term SGA infants have increased mortality when born to mothers
with pregnancy-induced hypertension.21 The greatest reduction in risk associated with
maternal hypertension was seen in the early preterm birth group, with moderate reduction
in mortality risk for late preterm infants, and an increase in risk or mortality for term
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infants born to mothers with hypertension. 21 These results are similar to our findings,
where the greatest reduction in mortality is seen at the lowest gestational ages when
infants are born to mothers with hypertension.
There is a clear link between growth restriction and maternal hypertension,
however that relationship varies with gestational age. Among SGA infants born at all
gestational ages, at participating New Zealand and Australian centers, 25.3% were born
to mothers with hypertension while 74.7% were born to normotensive mothers.22
Restricting to the preterm population yields very different results, as we report that 62.5%
of North American preterm SGA infants were born to hypertensive mothers.
A large meta-analysis demonstrated women with chronic hypertension have
increased risk of low birth weight, preterm birth, and SGA; antihypertensive treatment
was shown to exacerbate these risks, and for every 10 mmHg reduction in blood pressure
due to treatment, an average reduction of 145 gram reduction in fetal growth was
observed.23 Similarly, a population based Taiwanese study demonstrated an association
between women receiving vasodilators and risk of delivering low birth weight infants.24
One explanation for the observed improved survival of infants born to mothers
with hypertension is likely that comparatively, maternal hypertension is less damaging
for fetal development than other causes of growth restriction. These teratogenic
exposures include infections such as cytomegalovirus, rubella, syphilis, and
toxoplasmosis, malnutrition, chronic maternal diseases including kidney disease, clotting
disorders, heart disease, and sickle cell anemia, or maternal exposures to known
teratogens such as alcohol, drug abuse, or smoking. In effect, that would result in
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observed decreased mortality in infants born to mothers with hypertension that is not
related to hypertension, but is due to increased risk resulting from other causes of growth
restriction and preterm birth.
A notable limitation of our study comes from the inability to differentiate between
the differing maternal hypertensive diagnoses. As preeclampsia, chronic hypertension,
and pregnancy associated (gestational) hypertension have all been linked with SGA
infants and poor outcomes, our results are likely an underestimation of reduced risk of
mortality. By classifying births following a single high blood pressure reading as
maternal hypertension, the number of cases is likely an overestimation, resulting in some
SGA infants who are growth restricted due to other factors, and who may therefore face
an increased risk of mortality due to those factors.
Several studies have reported a large discrepancy between birth weight curves and
those using fetal growth parameters, particularly among extremely preterm infants.
Bernstein et al. noted significant differences in multiple cross-sectional studies
comparing birth weight growth curves and those derived from fetal ultrasound. The first
utilized regression lines comparing 350 birth weights at various gestational ages to 350
ongoing pregnancies, finding larger variability in the low gestational ages.25 A second,
larger study, reported more than 26% of preterm fetal weights were greater than the 90th
percentile, with less than 2% below the 10th percentile when compared to birth weight.26
These findings underscore that healthy fetuses with normal growth remain in utero, while
those who are growth restricted have high rates of preterm birth.
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When birth weight is used as the determination for appropriate growth, Zeitlin et
al. suggested a cut-off at the twenty-fifth percentile would be more appropriate for
identification of preterm infants at increased risk of mortality due to growth restriction.18
She reported increased odds of mortality of 3.98 (95% CI 2.79-5367) for infants with a
birth weight of less than the 10th percentile born between 24 at 31 weeks gestation, and
2.15 (95% CI 1.54-3.00) for infants in the 10-25th birth weight percentiles when
compared to those in the 50-75th percentile.18 The difference seen in growth curves
becomes less important with increasing gestational age, as infants born closer to term
have more comparison infants, and therefore have a more normal distribution of birth
weight, highlighting the potential value of a hybrid growth curve which combines fetal
and birth weight standards.27 As many as 65-73% of SGA infants born between 25 and
30 weeks gestation may be misclassified as AGA, while infants born at term are highly
unlikely to be misclassified due to the large number of comparison infants.28 This is
predominantly due to the health of infants born at particular gestational ages; term infants
are healthier and are more likely to have been able to reach their growth potential, while
preterm infants are faced with adverse intrauterine environments that impact growth
potential and contribute to preterm birth.
Misclassification of growth restricted infants’ results in only the most growth
restricted infants being classified as SGA. Infants born prior to 34 weeks gestation were
identified as SGA in 11.6% of the population using neonatal growth standards, but the
use of fetal growth standards resulted in 23.3% of the same infant pool who were growth
restricted.29 This discrepancy results in a population of growth-restricted infants who are
identified as being at increased risk of mortality according to birth weight standards, but
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using fetal standards results in SGA being associated with increased risk of morbidity,
including respiratory distress syndrome, bronchopulmonary dysplasia, interventricular
hemorrhage, retinopathy of prematurity.29 This population bias results in infants
identified as SGA who are the smallest of growth restricted infants, and who therefore
face the highest risk of mortality. Lackman et al. suggests the misidentification of at-risk
fetuses may play a role in high stillbirth rates for growth restricted infants because they
do not receive the increased prenatal monitoring given to pregnancies with known growth
restriction.30 This population bias clearly restricts the identification of infants included in
this analysis, however as our primary objective was to identify mortality risk in SGA
infants, we believe our use of birth weight curves for SGA identification is appropriate.
We expect that if we were to repeat the study using fetal or hybrid growth curves, SGA
infants born to hypertensive mothers would ultimately have lower rates of mortality and
likely, also of major morbidity.
Factors affecting mortality risk in preterm infants are numerous, and the choice
of variables included in multivariable models greatly impact results. Multivariable
models are better at predicting diagnostic and prognostic outcomes than simple
assessment of birth weight and gestational age. 31 The NICHD recognizes gestational age,
birth weight, sex, singleton status, and the reception of antenatal steroids in their
Extremely Preterm Birth Weight Outcome calculator.32 Mulitivariable modeling allows
for better inclusion of the overall perinatal period, multiple factors affecting outcome, and
changes in status. Similarly, inclusion of covariates, such as prenatal care and inborn
status at birth, which vary between groups, can be argued as being clinically relevant,
with regard to outcome as one group is biased towards receiving better clinical care than
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the other. As our results demonstrate, despite a significant univariate difference in which
the hypertension group was both more likely to be inborn and to receive prenatal care,
neither of these covariates affected the odds of mortality.
Preterm SGA infants have high mortality, but subsets of SGA infants appear to
have unique clinical outcomes. In this report we identify SGA infants born prior to 30
weeks gestation to hypertensive mothers have less mortality than other similar gestational
age SGA infants, particularly at the earliest gestational ages, and that maternal
hypertension is an independent predictor of outcome and should be considered in
neonatal prognosis.
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Table 4.1: Small for gestational age infant demographics and maternal
characteristics for infants born to mothers with and without hypertension.
No
Hypertension
(2,580)

Hypertension
(4,317)

88.5

90.7

76.1
95.8
60.4

95.5
98.3
52.8

28.0
44.1
20.4
7.5

32.6
40.5
20.3
6.7

562 ± 156

584 ± 159

26.6 ± 2.2
72.4
3.8 ± 2.5
43.1

26.9 ± 1.9
85.6
4.1 ± 2.4
28.9

Location*
Inborn
Cesarean Delivery*
Prenatal Care*
Male Sex*
Race*
(Black)
(White)
(Hispanic)
(Other)
Birth weight, grams
(mean ± SD)
Gestational Age, Weeks*
Antenatal Steroids*
1 minute Apgar*
Mortality Rate*

Individual characteristics marked with an asterisk are significantly different between groups (p<.05).
Values represent percent unless otherwise indicated.
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Figure 4.1: Incidence of small for gestational age infant birth at each gestational age by maternal
hypertension status.
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Figure 4.2: Infant mortality of SGA infant birth at each gestational age by maternal HTN status.

94

Table 4.2: The independent predictive value of maternal hypertension on mortality
in small for gestational age infants.

Hypertension
Birth Weight
Male Sex
(Ethnicity) Hispanic
(Race) Caucasian
(Race) Other
Location
Antenatal Steroids
Prenatal Care
Gestational Age

Odds Ratio 95% Confidence Interval
0.60
0.52 to 0.69
0.45
0.41 to 0.49
1.91
1.68 to 2.17
0.86
0.68 to 1.09
0.78
0.68 to 0.91
0.75
0.57 to 0.99
1.09
0.76 to 1.58
0.45
0.38 to 0.54
0.70
0.47 to 1.03
0.82
0.78 to 0.87

Odds ratios of relationship of mortality with all covariates in all SGA infants born 22+0 to 29+6 weeks GA.
Reference race is African American/Black.
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